Evidence map›Paper›PMID 38146190›Full record

ArticleInquiry : a journal of medical care organization, provision and financing

Study of Factors to Increase the Usage Rate of Generic Drugs in Platelet Aggregation Inhibitors.

Takaaki Suzuki, Mari Iwata, Mika Maezawa, Kiyoka Matsumoto, Mizuki Tanaka, Riko Satake, Misaki Inoue, Yu Yoshida, Kazuhiro Iguchi, Mitsuhiro Nakamura

Open access · goldAbstract read
In one paragraph

Article in Inquiry : a journal of medical care organization, provision and financing. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 73% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Takaaki SuzukiGifu Pharmaceutical University, Gifu, Japan.
Mari IwataGifu Pharmaceutical University, Gifu, Japan.
Mika MaezawaGifu Pharmaceutical University, Gifu, Japan.
Kiyoka MatsumotoGifu Pharmaceutical University, Gifu, Japan.
Mizuki TanakaGifu Pharmaceutical University, Gifu, Japan.
Riko SatakeGifu Pharmaceutical University, Gifu, Japan.
Misaki InoueGifu Pharmaceutical University, Gifu, Japan.
Yu YoshidaGifu Pharmaceutical University, Gifu, Japan.
Kazuhiro IguchiGifu Pharmaceutical University, Gifu, Japan.ORCID 0000-0003-1506-9804
Mitsuhiro NakamuraGifu Pharmaceutical University, Gifu, Japan.ORCID 0000-0002-5062-5522
Gifu Pharmaceutical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To reduce pharmacy-related medical expenses, it is necessary to reduce drug costs. One way to achieve this is by increasing the usage rate of generic drugs. The purpose of this study was to identify platelet aggregation inhibitors (PAIs) that contribute to high drug costs and are sold as brand-name drugs in order to increase the usage rate of generic drugs, and to analyze the factors that affect the usage rate of generic drug. We conducted a cross-sectional study based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan Open Data Japan (NODJ) of the Ministry of Health, Labor and Welfare and datasets containing related medical information from official statistical surveys such as the Basic Survey on Wage Structure. Monthly personal income in each prefecture were negatively correlated with outpatient out-of-hospital and outpatient in-hospital prescriptions of the PAIs clopidogrel (75 mg), cilostazol (50 mg), cilostazol (100 mg), and ticlopidine (100 mg), but not between monthly personal income and outpatient out-of-hospital prescription of ticlopidine (100 mg). For outpatient out-of-hospital prescriptions and outpatient in-hospital prescriptions, negative correlation was generally observed between the usage rate of generic drug and monthly personal income, except for ticlopidine (100 mg), which has the lowest price among the brand-name drugs. The usage rate of generic PAIs is negatively correlated with monthly personal income. Promoting the use of generic drugs among high-income earners might be necessary to further increase the usage rate of generic drug.

Indexed as

Drugs, GenericPlatelet Aggregation InhibitorsCilostazolCross-Sectional StudiesHumansTiclopidineCilostazolDrugs, GenericPlatelet Aggregation InhibitorsTiclopidinedrug costgeneric drughealth surveymonthly personal incomeNDB Open Data Japanplatelet aggregation inhibitor

Identifiers

PMID38146190
PMCPMC10752065
OpenAlexW4390240132

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.